Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR-145 through the ERK1/2 in non-small cell lung cancer

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1940-1946

  Guo, Yue Hui ^a   Zhang, Chao ^a   Shi, Jing ^a   Xu, Mang Hua ^a   Liu, Feng ^a   Yuan, Hai Hua ^a   Wang, Jiong Yi ^a   Jiang, Bin ^a   Gao, Feng Hou ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Lung cancer; MiR 145; Regulation; Signal transduction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA 145; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84904110196     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3021     Document Type: Article

References (30)

1. Pogribny IP: MicroRNA dysregulation during chemical carcinogenesis. Epigenomics 1: 281-290, 2009.
2. Takai D: Recent proceedings in epigenetics research of lung cancer. Nihon Rinsho 67: 2387-2396, 2009 (In Japanese).
3. Wang Q, Wang S, Wang H, Li P and Ma Z: MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment. Exp Biol Med 237: 227-235, 2012.
4. Kang J, Lee SY, Lee SY, et al: microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3. Exp Ther Med 3: 149-153, 2012.
5. Darido C, Georgy SR, Wilanowski T, et al: Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell 20: 635-648, 2011.
6. Lu Y, Govindan R, Wang L, et al: MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 33: 1046-1054, 2012.
7. Chen Z, Zeng H, Guo Y, et al: miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 29: 151, 2010.
8. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A and Lund AH: MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 5: e8836, 2010.
9. Dhomen NS, Mariadason J, Tebbutt N and Scott AM: Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 17: 31-50, 2012.
10. Ayoola A, Barochia A, Belani K and Belani CP: Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 30: 433-446, 2012.
11. Wang Y, Wang X, Zhang J, et al: MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. J Neurooncol 106: 217-224, 2012.
12. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15: 1191-1197, 1997.
13. Ellis AG, Doherty MM, Walker F, et al: Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 71: 1422-1434, 2006.
14. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
15. Burke WM, Jin X, Lin HJ, et al: Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20: 7925-7934, 2001.
16. Pene F, Claessens YE, Muller O, et al: Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21: 6587-6597, 2002.
17. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H and Namura S: Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 288: 163-166, 2000.
18. Seo IA, Lee HK, Shin YK, et al: Janus kinase 2 inhibitor AG490 inhibits the STAT3 signaling pathway by suppressing protein translation of gp130. Korean J Physiol Pharmacol 13: 131-138, 2009.
19. Walker EH, Pacold ME, Perisic O, et al: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6: 909-919, 2000.
20. Favata MF, Horiuchi KY, Manos EJ, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998.
21. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947, 2004.
22. Sachdeva M, Zhu S, Wu F, et al: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106: 3207-3212, 2009.
23. Takaoka Y, Shimizu Y, Hasegawa H, et al: Forced expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in concert with miR-145 in gut tumors of ApcMin Mice. PLoS One 7: e42137, 2012.
24. Zhou CH, Yang SF and Li PQ: Human lung cancer cell line SPC-A1 contains cells with characteristics of cancer stem cells. Neoplasma 59: 685-692, 2012.
25. Wang Z, Zhang X, Yang Z, et al: MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells. Biochem Biophys Res Commun 427: 444-449, 2012.
26. Gotte M, Mohr C, Koo CY, et al: miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 29: 6569-6580, 2010.
27. Eck MJ and Yun CH: Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta 1804: 559-566, 2010.
28. Mukohara T, Kudoh S, Yamauchi S, et al: Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41: 123-130, 2003.
29. Koivunen JP, Mermel C, Zejnullahu K, et al: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283, 2008.
30. Chen H, Kovar J, Sissons S, et al: A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal Biochem 338: 136-142, 2005.